Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 4/20 | 0.78 |
| ▸ | PIK3CD | O00329 | 17/20 | 0.59 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.57 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.57 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.57 |
| ▸ | MTOR | P42345 | 1/20 | 0.57 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.57 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12838018 | 0.88 | PIK3CA (0.61) | PIK3CAPIK3CD | |
| SCHEMBL12837962 | 0.88 | PIK3CA (0.61) | PIK3CAPIK3CD | |
| SCHEMBL12837963 | 0.87 | PIK3CA (0.60) | PIK3CAPIK3CDPIK3R2PIK3C2BPIK3CB | |
| SCHEMBL12838010 | 0.87 | PIK3CA (0.60) | PIK3CAPIK3CDPIK3R2PIK3C2BPIK3CB | |
| SCHEMBL12837961 | 0.87 | PIK3CA (0.60) | PIK3CAPIK3CD | |
| SCHEMBL1485478 | 0.87 | PIK3CA (1.00) | PIK3CAPIK3CDPIK3CG | |
| SCHEMBL12688800 | 0.85 | PIK3CA (0.76) | PIK3CAPIK3CDPIK3R2PIK3C2BPIK3CB | |
| SCHEMBL1485088 | 0.85 | PIK3CA (0.67) | PIK3CAPIK3CDPIK3R2PIK3C2BPIK3CB | |
| SCHEMBL12539623 | 0.85 | PIK3CA (0.65) | PIK3CAPIK3CDPIK3R2PIK3C2BPIK3CB | |
| SCHEMBL18659511 | 0.85 | PIK3CA (0.75) | PIK3CAPIK3CDPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170081341-A1 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2017-03-23 | — | — | US | disclosed |
| WO-2011036280-A1 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170081341-A1 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | BMX, PIK3CA, PI4KA | PIK3CA 2/4885PIK3CD 7/4885PIK3R2 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.